The FCA's interim findings as part of its Asset Management Market Study, released last November, should have left the industry in no doubt about the direction of travel for the sector over the coming months and years.
While some asset managers may have tried to convince themselves only groups running 'closet trackers' or product ranges where costs have not been kept under control should be concerned by the findings,...
BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.
Classes A and D remain unavailable
Has been sponsor since 2010
Hires RBC's Martin Heale
Bringing over two funds